• Active, not recruiting

NCT02136134: Phase 3 - Daratumumab Plus Bortezomib & Dexa in relapsed Myeloma MMY3004 (CASTOR) Study

Updated: Jun 15


The CASTOR Trial

Dara Vd

DVd


NCT02136134: Phase 3: Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma


CASTOR study

The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma


Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma


Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02136134


Official Title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : May 12, 2014


Click here for details on ClinicalTrials.gov

 

JNJ-54767414

 

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information


Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

 

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

PMID: 27557302 N Engl J Med; Aug 2016

https://pubmed.ncbi.nlm.nih.gov/27557302/


Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Conclusions: In this updated analysis of CASTOR, D-Vd maintains significant PFS and ORR benefits in RRMM, with the greatest benefit achieved by pts who received 1 PL of therapy. The safety profile of D-Vd remains consistent with longer follow-up, with no new safety concerns reported. These data continue to suggest that administration of D-Vd to RRMM pts after first relapse may provide the greatest clinical benefit.

653.Myeloma: Therapy, excluding Transplantation| November 13, 2019

https://doi.org/10.1182/blood-2019-123527


Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

PMID: 32819447 J Hematol Oncol; Aug 2020

https://pubmed.ncbi.nlm.nih.gov/32819447/



Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

PMID: 31221782 Haematologica; Jan 2020

https://pubmed.ncbi.nlm.nih.gov/31221782/



1655 Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison

Program: Oral and Poster Abstracts

Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster I

Hematology Disease Topics & Pathways:

Diseases, Combinations, Lymphoid Malignancies

Saturday, December 5, 2020, 7:00 AM-3:30 PM

https://ash.confex.com/ash/2020/webprogram/Paper141995.html

 

Locations

United States, Alabama

United States, California

United States, Connecticut

United States, Florida

United States, Georgia

United States, Illinois

United States, Kansas

United States, Louisiana

United States, Massachusetts

United States, Michigan

United States, New York

United States, North Carolina

United States, Oregon

United States, Pennsylvania

United States, Rhode Island

United States, Washington

Mexico

Australia

South America

Brazil

Europe

Czechia

Netherlands

Poland

Spain

Sweden

Germany

Hungary

Turkey

Ukraine

Asia

Korea, Republic of

Russian Federation



Posts Archive